Jean Jacques Bienaime - Dec 21, 2021 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Dec 21, 2021
Transactions value $
-$500,778
Form type
4
Date filed
1/14/2022, 07:45 PM
Previous filing
Dec 17, 2021
Next filing
Mar 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Small acquisition under Rule 16a-6 $8.92K +100 +0.03% $89.22 304K Dec 21, 2021 Direct
transaction BMRN Common Stock Options Exercise $187K +5K +1.65% $37.46 309K Jan 12, 2022 Direct F1
transaction BMRN Common Stock Sale -$445K -5K -1.62% $89.00 304K Jan 12, 2022 Direct F1, F2
transaction BMRN Common Stock Options Exercise $187K +5K +1.65% $37.46 309K Jan 13, 2022 Direct F1
transaction BMRN Common Stock Sale -$439K -5K -1.62% $87.86 304K Jan 13, 2022 Direct F1
holding BMRN Common Stock 248K Dec 21, 2021 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -5K -4% $0.00 120K Jan 12, 2022 Common Stock 5K $37.46 Direct F1, F3
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -5K -4.17% $0.00 115K Jan 13, 2022 Common Stock 5K $37.46 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on October 13, 2021.
F2 The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 50 shares, with the reporting person's purchase of shares at a price of $78.7700 on September 9, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.